LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Laboratoires Théa for the Canadian market, focusing on the eye drop treatment LNZ100 for presbyopia. The agreement secures over $70 million in upfront and milestone payments for LENZ, along with double-digit royalties on net sales. Théa, a prominent company in eye-care product commercialization, will handle the development, manufacturing, registration, and marketing of LNZ100 in Canada. This partnership marks LENZ's third international commercialization deal for LNZ100, underscoring its commitment to broadening patient access to this innovative therapy globally. Jean-Frédéric Chibret, President of Théa, highlighted the potential of this promising treatment to address a widespread condition affecting millions of adults in Canada.